APPLICATION OF THE CYP3A4 SELECTIVE MECHANISM-BASED INACTIVATOR CYP3CIDE TO DELINEATE CYP3A4 AND CYP3A5 CONTRIBUTIONS TO THE METABOLISM OF CYP3A CLEARED DRUGS

被引：0
|
作者：
Tseng, Elaine [1 ]
Walsky, Robert L. [2 ]
Luzietti, Rick [2 ]
Harris, Jennifer [2 ]
Kosa, Rachel E. [1 ]
Zientek, Michael A. [3 ]
Goosen, Theunis C. [1 ]
Obach, R. Scott [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton, CT USA
[2] AstraZeneca, Waltham, MA USA
[3] Pfizer Global Res & Dev, La Jolla, CA USA
来源：
DRUG METABOLISM REVIEWS | 2014年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [21] Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
    Williams, JA
    Ring, BJ
    Cantrell, VE
    Jones, DR
    Eckstein, J
    Ruterbories, K
    Hamman, MA
    Hall, SD
    Wrighton, SA
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (08) : 883 - 891
  • [22] Comparison of CYP3A4 and CYP3A5 in Drug Metabolism and Drug Interactions
    Li, Shuanmei
    Liu, Duan
    Zhu, Juanli
    Cui, Yan
    Zhou, Ruimin
    Chen, Chao
    DRUG METABOLISM REVIEWS, 2009, 41 : 31 - 32
  • [23] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by grapefruit juice and proadifen.
    Adigun, AQ
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P61 - P61
  • [24] Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
    Saiz-Rodriguez, Miriam
    Almenara, Susana
    Navares-Gomez, Marcos
    Ochoa, Dolores
    Roman, Manuel
    Zubiaur, Pablo
    Koller, Dora
    Santos, Maria
    Mejia, Gina
    Borobia, Alberto M.
    Rodriguez-Antona, Cristina
    Abad-Santos, Francisco
    BIOMEDICINES, 2020, 8 (04)
  • [25] Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
    Leel, Jin Sol
    Cheong, Hyun Sub
    Kim, Lyoung Hyo
    Kixn, Ji On
    Seo, Doo Won
    Kim, Young Hoon
    Chung, Myeon Woo
    Han, Soon Young
    Shin, Hyoung Doo
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2013, 17 (06): : 479 - 484
  • [26] NEW TOOLS TO DIFFERENTIATE CYP3A4 AND CYP3A5 ACTIVITY
    Li, Xiaohai
    Kamenecka, Theodore M.
    Jeso, Valer
    Micalizio, Glen
    Heyward, Scott
    Walker, Gregory S.
    Cameron, Michael D.
    DRUG METABOLISM REVIEWS, 2015, 47 : 70 - 70
  • [27] Differential inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang, Y
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [28] Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
    Kivisto, KT
    Bookjans, G
    Fromm, MF
    Griese, EU
    Munzel, P
    Kroemer, HK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (03) : 387 - 389
  • [29] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [30] CYP3A5 and not CYP3A4 is present in peripheral blood.
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Watkins, PB
    GASTROENTEROLOGY, 1996, 110 (04) : A1222 - A1222
12345